Metabolic Dysfunction-Associated Steatotic Liver Disease
Conditions
Keywords
MASLD, Rice Bran, Nutrition Education, Liver Steatosis, Functional Food, Body Weight
Brief summary
This study aims to evaluate the effects of nutrition education with or without rice bran supplementation in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants were recruited from the Division of Gastroenterology and Hepatology at Changhua Christian Hospital and assigned to either a nutrition education (NE) group or a nutrition education plus rice bran (NERB) group. The intervention was conducted for a specified study period, during which participants received dietary guidance and follow-up assessments. The primary objective of this study is to determine whether rice bran supplementation in addition to nutrition education provides greater benefits on body weight, body mass index, dietary intake, and metabolic parameters compared with nutrition education alone. Secondary outcomes include changes in liver-related biochemical markers, glycemic indicators, lipid profiles, and other anthropometric measurements. This study may provide evidence on the potential role of rice bran as a functional dietary supplement for improving metabolic health in patients with MASLD and may support the development of practical nutritional strategies for disease management.
Interventions
BEHAVIORALNutrition Education
Participants received structured nutrition education during the study period.
DIETARY_SUPPLEMENTRice Bran
Participants received structured nutrition education together with rice bran supplementation during the intervention period.
Sponsors
Shih Chien University
Changhua Christian Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* overweight or obese (BMI \> 24 kg/m²) * diagnosed by a physician with moderate fatty liver (grade II)
Exclusion criteria
* had stage 3 or higher chronic kidney disease * were undergoing treatment for malignant disease * had hepatitis B or hepatitis C infection or carrier status * had alcoholic hepatitis * had a known allergy to rice bran.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in body weight | From enrollment to the end of treatment at 3 months | Body weight was measured to evaluate the effect of nutrition education with or without rice bran supplementation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in body mass index | From enrollment to the end of treatment at 3 months | Body mass index was measured to evaluate the effect of nutrition education with or without rice bran supplementation. |
| Change in waist circumference | From enrollment to the end of treatment at 3 months | Waist circumference was measured to assess changes in central adiposity following the intervention. |
| Change in body fat percentage | From enrollment to the end of treatment at 3 months | Body fat percentage was measured to assess changes in body composition following the intervention. |
| Change in visceral fat area | From enrollment to the end of treatment at 3 months | visceral fat area was measured to assess changes in body composition following the intervention. |
| Change in energy intake | From enrollment to the end of treatment at 3 months | Energy intake was assessed to evaluate changes in dietary intake following the intervention. |
| Change in dietary fiber intake | From enrollment to the end of treatment at 3 months | Dietary fiber intake was assessed to evaluate changes in dietary quality following the intervention. |
| Change in fasting glucose | From enrollment to the end of treatment at 3 months | Fasting glucose was measured to assess the effect of the intervention on glycemic status. |
| Change in HbA1c | From enrollment to the end of treatment at 3 months | HbA1c was measured to assess the effect of the intervention on glycemic status. |
| Change in fasting insulin | From enrollment to the end of treatment at 3 months | Fasting insulin was measured to assess the effect of the intervention on insulin status. |
| Change in triglycerides | From enrollment to the end of treatment at 3 months | Triglyceride levels were measured to assess the effect of the intervention on lipid metabolism. |
| Change in HDL-cholesterol | From enrollment to the end of treatment at 3 months | HDL-cholesterol was measured to assess the effect of the intervention on lipid profile. |
| Change in LDL-cholesterol | From enrollment to the end of treatment at 3 months | LDL-cholesterol was measured to assess the effect of the intervention on lipid profile. |
| Change in alanine aminotransferase | From enrollment to the end of treatment at 3 months | Alanine aminotransferase was measured to assess the effect of the intervention on liver function. |
| Change in aspartate aminotransferase | From enrollment to the end of treatment at 3 months | Aspartate aminotransferase was measured to assess the effect of the intervention on liver function. |
| Change in FibroScan liver stiffness measurement (E, kPa) | From enrollment to the end of treatment at 3 months | FibroScan liver stiffness measurement was assessed to evaluate changes in liver stiffness following the intervention. |
| Change in FibroScan controlled attenuation parameter (CAP, dB/m) | From enrollment to the end of treatment at 3 months | FibroScan controlled attenuation parameter was assessed to evaluate changes in hepatic steatosis following the intervention. |
Countries
Taiwan
Outcome results
None listed